[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603947":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":53,"collaborators":11,"id":56,"slug":11,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":11,"eligibilityCriteria":60,"healthyVolunteers":57,"sex":61,"minAge":62,"maxAge":11,"enrollmentInfo":63,"targetDuration":11,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Colchicine group","ACTIVE_COMPARATOR",null,[13],"Drug: Colchicine",{"label":15,"type":16,"description":11,"interventionNames":17},"Control group","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Colchicine","Administration of Colchicine 1 day before and 90 days after PCI in Non-STEMI Patients",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Placebo","Matching Placebo Regimen",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Resident Doctor","CONTACT","+201272615212","david.17289616@med.aun.edu.eg",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":11,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Assiut University Hospitals","RECRUITING","Asyut","Asyut Governorate","Egypt",{"type":43,"coordinates":44},"Point",[45,46],31.18368,27.18096,{"lat":46,"lon":45},[49],{"name":50,"role":32,"phone":51,"phoneExt":11,"email":52},"Vice president of graduate studies of Assiut University","+2088 22080150","vp_grad@aun.edu.eg",{"type":54,"investigatorFullName":55,"investigatorTitle":31,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","David Gamal William Ibrahim","100603947",false,"NCT07143136","Short-Term Outcomes of Early Administration of Colchicine in Non-ST Segment Elevation Myocardial Infarction Patients Treated With Drug-Eluting Stents.","Inclusion Criteria:\n\n* Diagnosed with Non-STEMI\n* Undergoing PCI with drug-eluting stents\n\nExclusion Criteria:\n\n* Severe renal or hepatic dysfunction\n* Colchicine hypersensitivity\n* Active infection and active diarrhea.\n* Gastrointestinal intolerance\n* Pregnancy or breastfeeding.\n* Cardiogenic shock","ALL","18 Years",{"count":64,"type":65},140,"ESTIMATED","INTERVENTIONAL",[68],"EARLY_PHASE1","Inflammation plays a central role in the pathophysiology of atherosclerosis and in the progression of coronary artery. Colchicine, an anti-inflammatory agent traditionally used for gout and pericarditis, has emerged as a potential therapy in cardiovascular disease due to its ability to inhibit microtubule polymerization and suppress interleukin-1β and the NLRP3 inflammasome pathway.\n\nCOLCOT and LoDoCo2 trails have demonstrated the efficacy of colchicine in reducing cardiovascular events in patients with coronary artery disease.\n\nHowever, more recent trials, including OASIS 9 and COVERT-MI trials did not support the use of a short-term colchicine treatment at the acute phase of ST segment elevation myocardial infarction (STEMI) to reduce infarct size and improve outcomes. Limited data exist on the peri-procedural use of colchicine in non-ST elevation myocardial infarction patients undergoing PCI.\n\nThis study proposes to assess whether a loading dose of colchicine before PCI, followed by 3-months maintenance therapy, can improve short-term clinical outcomes and inflammatory markers in non- STEMI patients.",[71],"Non ST-Segment Elevation Myocardial Infarction",[22,73,74],"Inflammation","Non-STEMI","2025-08-19",{"date":77,"type":78},"2025-08-27","ACTUAL",{"date":80,"type":78},"2025-08-10",{"date":82,"type":65},"2026-09",{"name":5,"class":6},1]